Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19308016 | NOVEL COMPOUNDS | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19199523 | KITS FOR PREPARING AND DELIVERING PURIFIED CORTICOTROPIN | May 2025 | September 2025 | Allow | 4 | 1 | 0 | No | No |
| 18905498 | KITS FOR PREPARING AND DELIVERING PURIFIED CORTICOTROPIN | October 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18742691 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | June 2024 | January 2026 | Allow | 19 | 1 | 1 | Yes | No |
| 18731133 | COMPOSITIONS AND METHOD FOR TREATING ACUTE RADIATION SYNDROME | May 2024 | June 2025 | Allow | 13 | 1 | 0 | No | No |
| 18507346 | SWEET PROTEIN FROM TRUFFLE | November 2023 | July 2024 | Allow | 9 | 1 | 0 | No | No |
| 18496150 | KITS FOR PREPARING AND DELIVERING PURIFIED CORTICOTROPIN | October 2023 | September 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18490174 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | October 2023 | September 2025 | Allow | 23 | 1 | 1 | No | No |
| 18454319 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | August 2023 | February 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18235184 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | August 2023 | October 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18449457 | METHODS FOR TREATMENT OF AND PROPHYLAXIS AGAINST INFLAMMATORY DISORDERS | August 2023 | September 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18221440 | METHOD FOR DESIGNING RNA BINDING PROTEIN UTILIZING PPR MOTIF, AND USE THEREOF | July 2023 | January 2026 | Allow | 30 | 2 | 0 | No | No |
| 18217984 | COMPOSITIONS AND METHODS OF USE FOR SECRETOGLOBINS TO PROTECT THE GLYCOCALYX VIA INTERACTIONS WITH HEPARAN SULFATE PROTEOGLYCAN PROTEINS | July 2023 | October 2025 | Allow | 27 | 1 | 1 | No | No |
| 18270509 | PROCESS FOR MANUFACTURING PEPTIDE | June 2023 | February 2024 | Allow | 7 | 0 | 0 | No | No |
| 18342176 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | June 2023 | November 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 18332026 | PIC1 INHIBITION OF MYELOPEROXIDASE OXIDATIVE ACTIVITY IN AN ANIMAL MODEL | June 2023 | November 2024 | Allow | 17 | 1 | 0 | No | No |
| 18330135 | LIPOPEPTIDES FOR USE IN TREATING LIVER DISEASES AND CARDIOVASCULAR DISEASES | June 2023 | January 2025 | Allow | 19 | 1 | 0 | No | No |
| 18329659 | SYSTEM AND METHOD FOR PRODUCTION OF ON-DEMAND PROTEINS IN A PORTABLE UNIT FOR POINT OF CARE DELIVERY | June 2023 | October 2024 | Allow | 16 | 1 | 0 | No | No |
| 18327535 | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES | June 2023 | January 2025 | Allow | 19 | 1 | 0 | No | No |
| 18204672 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | June 2023 | February 2026 | Allow | 32 | 2 | 0 | No | No |
| 18204907 | Modulators of Complement Activity | June 2023 | October 2024 | Allow | 17 | 1 | 0 | No | No |
| 18312330 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | May 2023 | April 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18312203 | PREPARATION METHOD OF SETMELANOTIDE BY CYCLIZATION OF DISULFIDE BOND IN SOLID PHASE | May 2023 | August 2025 | Allow | 27 | 1 | 0 | No | No |
| 18133372 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | April 2023 | September 2025 | Abandon | 30 | 2 | 0 | No | Yes |
| 18128062 | Antifungal Peptides, Compounds Including The Same, And Methods Of Use Thereof | March 2023 | November 2023 | Allow | 8 | 1 | 0 | No | No |
| 18173506 | COLLAGEN FIBER-BASED INK AND METHODS OF USE FOR BIOPRINTING | February 2023 | August 2024 | Allow | 17 | 2 | 1 | No | No |
| 18168792 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | February 2023 | August 2025 | Allow | 30 | 2 | 1 | No | No |
| 18169149 | CHILI PEPPER SEED ISOLATED OLIGOPEPTIDE FTLE AND APPLICATION THEREOF IN PREVENTING OR TREATING CANCER | February 2023 | September 2023 | Allow | 7 | 1 | 0 | No | No |
| 18159021 | PEPTIDE COMPOSITIONS AND METHODS OF USE | January 2023 | November 2024 | Allow | 22 | 2 | 0 | No | No |
| 18155747 | TOPICAL APPLICATION OF POLYPEPTIDE IN THE TREATMENT OF SKIN DAMAGE | January 2023 | September 2025 | Allow | 32 | 0 | 0 | No | No |
| 18092737 | HMGN PARTIAL PEPTIDE AND CANCER THERAPY USING THE SAME | January 2023 | November 2023 | Allow | 10 | 1 | 0 | No | No |
| 18145730 | USE OF SOLUBLE PRO(RENIN) RECEPTOR TO TREAT METABOLIC DISORDERS AND RELATED CONDITIONS | December 2022 | October 2023 | Allow | 10 | 0 | 0 | No | No |
| 18063397 | SMAC/DIABLO INHIBITORS USEFUL FOR TREATING CANCER | December 2022 | January 2024 | Allow | 13 | 1 | 0 | No | No |
| 18062534 | TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF | December 2022 | January 2024 | Allow | 13 | 1 | 0 | No | No |
| 18062435 | COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA | December 2022 | January 2025 | Allow | 25 | 2 | 0 | No | Yes |
| 18062028 | APPLICATION OF SKELETAL MUSCLE SECRETED FACTOR THBS4 IN PREPARATION OF DRUG FOR IMPROVING SYSTEMIC GLUCOSE AND LIPID METABOLISM | December 2022 | January 2024 | Allow | 13 | 1 | 0 | No | No |
| 18061238 | ANTI-ALLERGIC PEPTIDE AND USE THEREOF FOR IMMUNE REGULATION AND ANTI-ALLERGY | December 2022 | August 2024 | Allow | 21 | 2 | 1 | No | No |
| 18074275 | TARGETING ANABOLIC DRUGS FOR ACCELERATED FRACTURE REPAIR | December 2022 | February 2025 | Allow | 26 | 1 | 0 | No | No |
| 18070125 | NOVEL PEPTIDES AND ANTI-CANCER COMPOSITIONS INCLUDING THEREOF | November 2022 | April 2024 | Allow | 16 | 2 | 0 | No | No |
| 18058516 | METHOD FOR PREVENTING HUMAN CELL INFECTION BY HERPESVIRUSES | November 2022 | May 2024 | Allow | 17 | 2 | 0 | No | No |
| 18056843 | COMPOSITIONS AND METHODS FOR INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER | November 2022 | April 2024 | Allow | 17 | 1 | 0 | No | No |
| 18057127 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | November 2022 | June 2024 | Allow | 19 | 1 | 1 | No | No |
| 17985012 | GLYPICAN-3-BINDING FIBRONECTIN BASED SCAFFOLD MOLECULES | November 2022 | July 2025 | Allow | 32 | 2 | 1 | No | No |
| 17984642 | METHOD FOR PREPARING NATURAL BIOACTIVE PEPTIDE TUBULYSIN U | November 2022 | May 2023 | Allow | 6 | 0 | 0 | No | No |
| 18048025 | Method for treating gingivitis and gingival atrophy and repairing oral mucosa | October 2022 | June 2025 | Allow | 32 | 2 | 0 | No | No |
| 17963700 | Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases | October 2022 | July 2025 | Allow | 33 | 3 | 0 | Yes | No |
| 17964023 | SYSTEMS AND METHODS OF TREATING PROSTATE CANCER | October 2022 | February 2025 | Allow | 28 | 2 | 0 | Yes | Yes |
| 17954929 | METHOD OF SUGAR-GUIDED MODIFYING GLYCOSYLATED POLYPEPTIDE AND APPLICATION OF THE SAME | September 2022 | July 2023 | Allow | 9 | 0 | 0 | No | No |
| 17941090 | Anti-Viral Compounds | September 2022 | March 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17821669 | ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE | August 2022 | May 2025 | Abandon | 33 | 2 | 0 | No | No |
| 17801671 | GENETICALLY ENGINEERED MICROORGANISMS THAT OVEREXPRESS MICROCIN-MGE AND METHODS OF PURIFICATION AND USE | August 2022 | November 2025 | Allow | 39 | 2 | 2 | No | No |
| 17890906 | TAXOL CONJUGATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | August 2022 | January 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 17811945 | CAR-T CELLS TARGETING GLIOMA STEM CELLS FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME | July 2022 | January 2024 | Allow | 18 | 1 | 0 | No | No |
| 17791997 | HUMAN ANTIBODIES TO RIFT VALLEY FEVER VIRUS | July 2022 | March 2026 | Allow | 44 | 1 | 1 | No | No |
| 17853591 | MEANS AND METHODS FOR SITE-SPECIFIC FUNCTIONALIZATION OF POLYPEPTIDES | June 2022 | November 2023 | Allow | 17 | 1 | 0 | No | No |
| 17757712 | OIL-IN-WATER EMULSIFIED COSMETIC | June 2022 | November 2025 | Allow | 41 | 1 | 0 | No | No |
| 17841093 | WOOD VINEGAR CONTAINING PRODUCT AND METHODS TO CONTROL ALGAE BLOOMS, REDUCE ODORS, AND OTHER APPLICATIONS | June 2022 | October 2025 | Allow | 40 | 3 | 1 | No | No |
| 17839635 | METHODS FOR PREVENTING OR TREATING CERTAIN DISORDERS BY INHIBITING BINDING OF IL-4 AND/OR IL-13 TO THEIR RESPECTIVE RECEPTORS | June 2022 | September 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17837772 | MICROSCALE BIOPROCESSING SYSTEM AND METHOD FOR PROTEIN MANUFACTURING FROM HUMAN BLOOD | June 2022 | October 2024 | Allow | 28 | 2 | 0 | No | No |
| 17832813 | GHRELIN O-ACYLTRANSFERASE (GOAT) IMAGING AGENTS | June 2022 | March 2026 | Abandon | 45 | 1 | 0 | No | No |
| 17781542 | Methods for Treating Osteoarthritis | June 2022 | February 2026 | Allow | 45 | 1 | 1 | No | No |
| 17827244 | MALASSEZIA FACTOR WITH ANTIBIOTIC ACTIVITY | May 2022 | July 2023 | Allow | 14 | 1 | 0 | No | No |
| 17752664 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | May 2022 | September 2025 | Allow | 40 | 5 | 1 | Yes | No |
| 17663028 | JNK INHIBITORS FOR USE IN TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | May 2022 | May 2025 | Allow | 36 | 3 | 1 | No | No |
| 17736113 | METHOD FOR MANUFACTURING A STABLE EMULSION FOR PEPTIDE DELIVERY | May 2022 | January 2024 | Allow | 20 | 1 | 0 | No | No |
| 17659974 | COMBINED THERAPY FOR TREATING ALZHEIMER'S DISEASE | April 2022 | July 2023 | Allow | 15 | 0 | 0 | No | No |
| 17659934 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN | April 2022 | July 2024 | Allow | 27 | 1 | 1 | No | No |
| 17723921 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | April 2022 | March 2025 | Allow | 35 | 2 | 1 | No | No |
| 17724304 | MODULATION OF COMPLEMENT ACTIVITY | April 2022 | August 2022 | Allow | 4 | 0 | 0 | Yes | No |
| 17718233 | ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE | April 2022 | March 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17704960 | SITE-SPECIFIC CONJUGATION TO ANTIBODY LYSINE RESIDUES WITH SOLID-PHASE IMMOBILIZED MICROBIAL TRANSGLUTAMINASE MTG AND MTG IN SOLUTION | March 2022 | March 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17762984 | COMPOSITIONS AND METHODS FOR TREATING DEGENERATIVE, AGE-RELATED AND TRAUMA-INDUCED DISORDERS | March 2022 | January 2026 | Allow | 46 | 1 | 1 | No | No |
| 17697646 | SYSTEMS, COMPOSITIONS AND METHODS FOR TREATING DIABETES | March 2022 | March 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17689631 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | March 2022 | March 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17641346 | Engineered Peptide and Peptide Mimetic Compositions and Methods | March 2022 | February 2026 | Allow | 48 | 2 | 1 | Yes | No |
| 17681166 | STABILIZED COLOSTRUM COMPOSITIONS | February 2022 | December 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17680818 | SWEET PROTEIN FROM TRUFFLE | February 2022 | October 2023 | Allow | 20 | 0 | 1 | No | No |
| 17637189 | PEPTIDE AMIDE COMPOSITION AND PREPARATION METHOD THEREFOR | February 2022 | November 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17673603 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | February 2022 | November 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17582368 | MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE | January 2022 | August 2024 | Allow | 31 | 2 | 0 | No | No |
| 17629333 | METHODS AND COMPOSITIONS FOR TREATING ANDROGEN RECEPTOR DEFICIENT, ANDROGEN RECEPTOR LOW, AND CASTRATION-RESISTANT PROSTATE CANCERS | January 2022 | September 2025 | Allow | 44 | 1 | 1 | No | No |
| 17626574 | COMPOSITIONS FOR TREATMENT OF INFERTILITY CAUSED BY POOR SEMEN QUALITY, METHODS FOR PREPARING THE SAME AND APPLICATIONS THEREOF | January 2022 | December 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17572115 | MELANOCORTIN RECEPTOR LIGANDS | January 2022 | May 2025 | Abandon | 40 | 2 | 0 | No | Yes |
| 17626025 | HIGH CONCENTRATION INSULIN FORMULATION | January 2022 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17568281 | IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS | January 2022 | November 2023 | Allow | 23 | 1 | 0 | No | No |
| 17568251 | COMPOSITIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF CANCER IMMUNOTHERAPY | January 2022 | December 2023 | Allow | 23 | 1 | 0 | No | No |
| 17559692 | RELEASABLE GLP-1 CONJUGATES | December 2021 | September 2023 | Allow | 21 | 1 | 0 | No | No |
| 17557628 | S-NITROSOGLUTATHIONE (GSNO) AND GSNO REDUCATASE INHIBITORS FOR USE IN THERAPY | December 2021 | February 2026 | Abandon | 50 | 7 | 1 | No | Yes |
| 17555958 | PSMA TARGETED CONJUGATE COMPOUNDS AND USES THEREOF | December 2021 | July 2024 | Allow | 31 | 2 | 0 | No | No |
| 17554650 | METHOD FOR THE DESIGN OF FIBRILLAR COLLAGEN-MIMETIC PEPTIDE SELF-ASSEMBLIES | December 2021 | August 2024 | Allow | 32 | 1 | 1 | No | No |
| 17552499 | USE OF COLLAGEN HYDROLYSATE FOR IMPROVING ENDURANCE PERFORMANCE AND FOR STIMULATING LIPID CATABOLISM | December 2021 | May 2024 | Allow | 29 | 1 | 1 | No | No |
| 17617267 | METHODS TO TREAT VIRAL INFECTIONS | December 2021 | September 2024 | Allow | 33 | 1 | 0 | Yes | No |
| 17616512 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF | December 2021 | October 2025 | Allow | 47 | 2 | 1 | No | No |
| 17596102 | DESIGNED ANKYRIN REPEAT DOMAIN WITH IMPROVED STABILITY | December 2021 | July 2025 | Allow | 43 | 1 | 1 | No | No |
| 17616146 | BETA-STRAND BRIDGE PEPTIDE | December 2021 | March 2026 | Allow | 51 | 2 | 1 | No | No |
| 17538971 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | November 2021 | October 2023 | Allow | 22 | 1 | 0 | No | No |
| 17614680 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | November 2021 | July 2025 | Allow | 44 | 1 | 1 | No | No |
| 17614236 | PPR PROTEIN CAUSING LESS AGGREGATION AND USE OF THE SAME | November 2021 | October 2025 | Allow | 47 | 0 | 1 | Yes | No |
| 17526327 | COMPOSITIONS OF HYBRID SUPPORTED LIPID BILAYERS AND METHODS FOR PRODUCING | November 2021 | November 2025 | Allow | 48 | 3 | 0 | No | Yes |
| 17518206 | LONG-ACTING FATTY ACID-CONJUGATED GnRH DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | November 2021 | February 2024 | Allow | 27 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LIEB, JEANETTE M.
With a 60.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 38.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner LIEB, JEANETTE M works in Art Unit 1654 and has examined 549 patent applications in our dataset. With an allowance rate of 79.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.
Examiner LIEB, JEANETTE M's allowance rate of 79.8% places them in the 49% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by LIEB, JEANETTE M receive 1.20 office actions before reaching final disposition. This places the examiner in the 15% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by LIEB, JEANETTE M is 25 months. This places the examiner in the 78% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +21.3% benefit to allowance rate for applications examined by LIEB, JEANETTE M. This interview benefit is in the 66% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 38.0% of applications are subsequently allowed. This success rate is in the 87% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 48.0% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 78.3% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 61.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 77.3% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 61% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.4% of allowed cases (in the 64% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.